

MADRID
2014

ESMO congress

esmocongress.org

ADVANCED PROGRAMME

ESMO 2014

Madrid, Spain

26-30 SEPTEMBER 2014

IMPORTANT DEADLINES

07 May 2014	Abstract submission and travel grant applications
18 June 2014	Early registration
23 July 2014	Group registration, participant names to be given
20 August 2014	Late-breaking abstract submission
20 August 2014	Late registration

Organiser

ESMO GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE
European Society for Medical Oncology

BASIC SCIENCE AND TRANSLATIONAL RESEARCH

Saturday, 27 September 2014

- 10:30/ 11:30 **PATIENT CASES**
Cancer evolution: What can we learn from N=1 molecular studies?
Co-Chairs: Michael Taylor, Toronto, ON, Canada and Tariq Enver, London, UK
Evolution of acute lymphoblastic leukemia (ALL) in identical twins
Tariq Enver, London, UK
Clonal evolution of childhood cancers
Michael Taylor, Toronto, ON, Canada
Discussion

Sunday, 28 September 2014

- 09:15/ 10:45 **JOINT SYMPOSIUM: ESMO - JSMO**
How to implicate genome sequencing data in oncology
Co-Chairs: Jean-Yves Douillard, St. Herblain, France and Atsushi Ohtsu, Kashiwa, Japan
Introduction
Jean-Yves Douillard, St. Herblain, France
Potentially druggable gene alterations in gastrointestinal cancer
Tatsuhiro Shibata, Tokyo, Japan
A new molecular taxonomy for colorectal cancer – What are the therapeutic implications?
To be announced
New insight of sequencing data in lung cancer
Kazuto Nishio, Osaka, Japan
Overcoming implementation challenges of personalised cancer therapy in patients with breast cancer
Fabrice André, Villejuif, France
Conclusions
Atsushi Ohtsu, Kashiwa, Japan

- 13:00/ 13:45 **KEYNOTE LECTURE**
Reclassifying cancer through genomics
Chair: Jos Jonkers, Amsterdam, Netherlands
Speaker: Michael Stratton, London, UK

Monday, 29 September 2014

- 11:00/ 12:30 **SPECIAL SYMPOSIUM**
Genomic instability from bench to bedside
Chair: Sheila Singh, Hamilton, ON, Canada
Co-Chair: Charles Swanton, London, UK
Introduction
Charles Swanton, London, UK
The emerging role of HELQ in homologous recombination repair in ovarian cancer
Rebecca Burrell, London, UK
Replication stress and DNA damage response in solid tumours
Jiri Bartek, Copenhagen, Denmark
The interface between cancer numerical and structural chromosomal instability: Mechanisms accelerating cancer diversity
René Medema, Amsterdam, Netherlands
Targeting cancer aneuploidy: Light at the end of the tunnel?
Tak Mak, Toronto, ON, Canada
Conclusions and clinical perspectives
Sheila Singh, Hamilton, ON, Canada

SCIENTIFIC COMMITTEE

Charles Swanton, London, UK, Chair

Jiri Bartek, Copenhagen, Denmark
René Bernards, Amsterdam, Netherlands
Rebecca Burrell, London, UK
Carlos Caldas, Cambridge, UK
Robert Gatenby, Tampa, FL, US
Ramaswamy Govindan, St. Louis, MO, US

Jos Jonkers, Amsterdam, Netherlands
Tak Mak, Toronto, ON, Canada
Carlo Maley, San Francisco, CA, USA
Sheila Singh, Hamilton, ON, Canada
Yosef Yarden, Rehovot, Israel

BREAST CANCER

Saturday, 27 September 2014

09:00/ 10:30 EDUCATIONAL SESSION **Update in the management of metastatic breast cancers**

Chair: Angelo Di Leo, Prato, Italy

Co-Chair: Herman Cortes-Funes, Madrid, Spain

Integration of molecular analyses in the management of metastatic breast cancer

Nicholas Turner, London UK

Hormonal therapy

Ian Smith, London, UK

Optimal therapy for R2 positive

Angelo Di Leo, Prato, Italy

11:00/ 12:30 EDUCATIONAL SESSION **Management of breast cancer in specific populations**

Chair: Fatima Cardoso, Lisbon, Portugal

Co-Chair: to be announced

Management of breast cancer in elderly patients

Etienne Brain, Saint Cloud, France

Management of breast cancer in very young and pregnant women

Sybille Loibl, Neu-Isenburg, Germany

Management of breast cancer in males

Fatima Cardoso, Lisbon, Portugal

16:00/ 17:30 EDUCATIONAL SESSION (REPETITION) **Management of breast cancer in specific populations**

Chair: Fatima Cardoso, Lisbon, Portugal

Co-Chair: to be announced

Management of breast cancer in elderly patients

Etienne Brain, Saint Cloud, France

Management of breast cancer in very young and pregnant women

Sybille Loibl, Neu-Isenburg, Germany

Management of breast cancer in males

Fatima Cardoso, Lisbon, Portugal

Sunday, 28 September 2014

08:00/ 09:00 PATIENT CASES **Targeting intrinsic subtypes of metastatic breast cancer: The spectrum of sensitivity to endocrine therapy**

Co-Chairs: Philippe Bedard, Toronto, ON, Canada and Javier Cortes, Barcelona, Spain

Overcoming resistance in ER positive disease

Philippe Bedard, Toronto, ON, Canada

Dealing with heterogeneity of triple negative breast cancer: From luminal androgen receptor to mesenchymal stem like subtype

Javier Cortes, Barcelona, Spain

Discussion

09:15/ 10:45 SPECIAL SYMPOSIUM **Residual disease after neoadjuvant therapies**

Chair: Evandro de Azambuja, Brussels, Belgium

Co-Chair: Suzette Delaloge, Villejuif, France

Introduction

Suzette Delaloge, Villejuif, France

Quantifying post-neo adjuvant therapy residual disease and its impact on relapse risk

Fraser Symmans, Houston, TX, US

Biological profiling of residual disease

Frederique Penault-Llorca, Clermont-Ferrand, France

Molecular imaging: Are we able to predict for residual disease?

Andreas Makris, Northwood, UK

How to design clinical trials in a post neo-adjuvant setting?

Andrew Tutt, London, UK

Conclusions and clinical perspectives

Evandro de Azambuja, Brussels, Belgium

14:15/ 15:45 EDUCATIONAL SESSION (REPETITION) **Update in the management of metastatic breast cancers**

Chair: Angelo Di Leo, Prato, Italy

Co-Chair: Herman Cortes-Funes, Madrid, Spain

Integration of molecular analyses in the management of metastatic breast cancer

Nicholas Turner, London UK

Hormonal therapy

Ian Smith, London, UK

Optimal therapy for R2 positive

Angelo Di Leo, Prato, Italy

SCIENTIFIC COMMITTEE (EARLY STAGE) Evandro De Azambuja, Brussels, Belgium, Chair

Hatem Azim, Brussels, Belgium
Agusti Barnadas, Barcelona, Spain
Fatima Cardoso, Lisbon, Portugal
Boon Chua, Melbourne, Australia
Angelo Di Leo, Prato, Italy
Peter Dubsy, Vienna, Austria

Sabine C. Linn, Amsterdam, Netherlands
Carlo Palmieri, Liverpool, UK
Alastair Thompson, Dundee, UK
Andrew Tutt, London, UK
Giuseppe Viale, Milan, Italy

Monday, 29 September 2014

08:00/09:00 **CHALLENGE YOUR EXPERT (CYE)**
Adjuvant treatment of breast cancer
Speaker: Martine Piccart, Brussels, Belgium

09:15/10:45 **SPECIAL SYMPOSIUM**
Cancer immunotherapy in breast cancer: Dream or reality?

Chair: Giuseppe Curigliano Milan, Italy
Co-Chair: Sherene Loi, Melbourne, Australia

Introduction

Giuseppe Curigliano Milan, Italy

Modulation of immune response in breast cancer and clinical implications of tumour dormancy
Sherene Loi, Melbourne, Australia

Diagnostic and therapeutic implications of tumour-infiltrating lymphocytes in breast cancer
Carsten Denkert, Berlin, Germany

Contribution of immune response to anti-tumour effect of chemotherapy
Carmen Criscitiello, Naples, Italy

Design of the ideal trial with immunotherapeutics
Giuseppe Curigliano Milan, Italy

Conclusions and clinical perspectives
Sherene Loi, Melbourne, Australia

14:15/15:45 **JOINT SYMPOSIUM: ESMO - ESTRO - ESSO**
Integration of local therapy with systemic treatment in oligometastatic breast cancer

Co-Chairs: Christoph Zielinski, Vienna, Austria; Philip Poortmans, Tilburg, Netherlands and Riccardo A. Audisio, St. Helens, UK

Introduction

Christoph Zielinski, Vienna, Austria

Combining systemic treatment with radiation therapy:
Quantifying the therapeutic gain
Per Karlsson, Gothenburg, Sweden

Design of clinical trials integrating local treatments with systemic therapy for M1 disease
To be announced

The role of surgery for M1 breast cancer
Marjut Leidenius, Helsinki, Finland

The role of radiation therapy for M1 breast cancer
Philip Poortmans, Tilburg, Netherlands

Conclusions
Riccardo A. Audisio, St. Helens, UK

16:00/17:00 **PATIENT CASES**
Challenges in managing breast cancer in young patients

Co-Chairs: Hatem A. Azim, Brussels, Belgium; Marco Colleoni, Milan, Italy and Sabine Linn, Amsterdam, Netherlands

Genetic testing: When and for whom?
Sabine Linn, Amsterdam, Netherlands

Fertility counselling: What are the options?
Hatem A. Azim, Brussels, Belgium,

Optimal adjuvant hormonal therapy in premenopausal women
Marco Colleoni, Milan, Italy

Discussion

Tuesday, 30 September 2014

08:00/09:00 **CYE (REPETITION)**
Adjuvant treatment of breast cancer
Speaker: Martine Piccart, Brussels, Belgium

SCIENTIFIC COMMITTEE (METASTATIC)

Giuseppe Curigliano, Milan, Italy, Chair

Philippe Bedard, Toronto, ON, Canada
Javier Cortes, Barcelona, Spain
Carmen Criscitiello, Milan, Italy
Carsten Denkert, Berlin, Germany
Luca Gianni, Milan, Italy
Roger Gomis, Barcelona, Spain

Per Karlsson, Gothenburg, Sweden
Antonio Llombart, Valencia, Spain
Sherene Loi, Melbourne, Australia
Sibylle Loibl, Neu-Isenburg, Germany
Nicholas Turner, London, UK

Sunday, 28 September 2014

09:15/ EDUCATIONAL SESSION

10:45 **Actual issues in neurooncology**

Chair: Roger Stupp, Zurich, Switzerland

Co-Chair: Mario Campone, St. Herblain, France

Brain metastases: To treat or not to treat?

Roger Stupp, Zurich, Switzerland

Molecular marker-based clinical decision-making today

Michael Weller, Zurich, Switzerland

Approaches to recurrent glioblastoma

Alba Brandes, Bologna, Italy

11:45/ PATIENT CASES

12:45 **Response, neurological function and other objectives in the management of patients with brain metastases**

Co-Chairs: Martin Bendszus, Heidelberg, Germany; Anthony Chalmers, Glasgow, UK, and Enrico Franceschi, Bologna, Italy

What type of radiotherapy is indicated in brain metastases?

Anthony Chalmers, Glasgow, UK

Systemic therapy instead or in addition to irradiation?

Enrico Franceschi, Bologna, Italy

Challenges and pitfalls in radiological response assessment of brain metastases

Martin Bendszus, Heidelberg, Germany

Discussion

14:15/ SPECIAL SYMPOSIUM

15:45 **Current concepts and future avenues in meningioma**

Chair: Jörg-Christian Tonn, Munich, Germany

Co-Chair: Matthias Preusser, Vienna, Austria

Introduction

Jörg-Christian Tonn, Munich, Germany

Meningioma: What can we learn from the biology for precision medicine?

Michel Kalamirides, Paris, France

Classification and molecular pathology of meningiomas

Christian Mawrin, Magdeburg, Germany

Radiotherapy of meningiomas

Damien Weber, Geneva, Switzerland

Molecular targeted, systemic therapies for meningiomas

Matthias Preusser, Vienna, Austria

Conclusions and clinical perspectives

Matthias Preusser, Vienna, Austria

SCIENTIFIC COMMITTEE

Roger Stupp, Zurich, Switzerland, Chair

Carmen Balaña, Barcelona, Spain

Elizabeth Cohen-Jonathan-Moyal, Toulouse, France

Enrico Franceschi, Bologna, Italy

Evanthia Galanis, Rochester, MN, USA

Khé Hoang-Xuan, Paris, France

Stefan Pfister, Heidelberg, Germany

Matthias Preusser, Vienna, Austria

Guido Reifenberger, Düsseldorf, Germany

Joan Seoane, Barcelona, Spain

Martin van den Bent, Rotterdam, Netherlands

Colin Watts, Cambridge, UK

Saturday, 27 September 2014

- 09:15/ 10:45 **JOINT SYMPOSIUM: ESMO - CSCO**
Global collaboration in phase I cancer drug development
Co-Chairs: Yi-Long Wu, Guangzhou, China and to be announced
 Introduction
Yi Long Wu, Guangzhou, China
 Phase I cancer drug development in China
Jin Li, Shanghai, China
 Phase I cancer drug development in Europe
To be announced
 How can pharmaceutical companies facilitate this global effort?
To be announced
 Lung Cancer Asia Study Group: East
Yi-Long Wu, Guangzhou, China
 Conclusions
To be announced

Sunday, 28 September 2014

- 09:00/ 10:30 **SPECIAL SYMPOSIUM**
Molecular profiling: Challenges and perspectives
Chair: Christian Dittich, Vienna, Austria
Co-Chair: Jean-Charles Soria, Villejuif, France
 Introduction
Jean-Charles Soria, Villejuif, France
 How to design the trials to meet the perspectives of personalised cancer medicine
Sumithra Mandrekar, Rochester, NY, US
 Platforms for tumour sequencing: Pertinence and practicability
Martijn Lolkema, Utrecht, Netherlands
 Overview of trials testing tumour molecular profiling
Jean-Charles Soria, Villejuif, France
 Targets, targets everywhere but not a drug to give
Udai Banerji, London, UK
 Conclusions and clinical perspectives
Christian Dittich, Vienna, Austria

Monday, 29 September 2014

- 10:30/ 11:30 **PATIENT CASES**
Demonstrating the emergence of resistance
Co-Chairs: Elisabeth de Vries, Groningen, Netherlands, and Ruth Plummer, Newcastle upon Tyne, UK
 How to overcome drug resistance
Ruth Plummer, Newcastle upon Tyne, UK
 Molecular imaging to demonstrate changes in tumour characteristics over the time
Elisabeth de Vries, Groningen, Netherlands
 Discussion
-
- 13:00/ 13:50 **KEYNOTE LECTURE**
Rational drug combinations
Chair: Timothy Yap, Sutton, UK
 Concepts and pre-clinical proof of principle
René Bernards, Amsterdam, Netherlands
 Clinical results and future perspectives
Jan Schellens, Amsterdam, Netherlands

SCIENTIFIC COMMITTEE Christian Dittich, Vienna, Austria, Chair

Ahmad Awada, Brussels, Belgium
 Udai Banerji, Sutton, UK
 Elisabeth de Vries, Groningen, Netherlands
 Elizabeth A. Eisenhauer, Kingston, ON, Canada
 Manuel Hidalgo, Madrid, Spain
 Annette K. Larsen, Paris, France

Ruth Plummer, Newcastle upon Tyne, UK
 Roberto Salgado, Brussels, Belgium
 Patrick Schöffski, Leuven, Belgium
 Giampaolo Tortora, Verona, Italy
 Christopher Twelves, Leeds, UK

FAMILIAL CANCERS AND GENETIC SYNDROMES

Saturday, 27 September 2014

- 09:15/ 10:45 **SPECIAL SYMPOSIUM**
Germline genetics: Important issues for oncologists
Chair: Dominique Stoppa-Lyonnet, Paris, France
Co-Chair: Rosalind Eeles, Sutton, UK
- Introduction
Dominique Stoppa-Lyonnet, Paris, France
- Current application of genetic variants to clinical management
Gareth Evans, Sutton, UK
- Considerations for the oncologist when referring for testing:
Which tests are available and why?
Thierry Frebourg, Rouen, France
- Genetic risk and its implications for cancer surveillance
Rosalind Eeles, Sutton, UK
- Considerations for the oncologist when treating cancer patients
with germline mutations
Gillian Mitchell, Melbourne, Australia
- Conclusions and clinical perspectives
Rosalind Eeles, Sutton, UK

Sunday, 28 September 2014

- 09:15/ 10:15 **PATIENT CASES**
Clinical and ethical issues in cancer genetics
Co-Chairs: Anneke Lucassen, Southampton, UK and
Fred Menko, Amsterdam, Netherlands
- Early onset renal cancer
Fred Menko, Amsterdam, Netherlands
- Ethical issues surrounding genetic results
Anneke Lucassen, Southampton, UK
- Discussion

SCIENTIFIC COMMITTEE Rosalind Eeles, Sutton, UK, Chair

Judith Balmaña, Barcelona, Spain
Elena Castro, Sutton, UK
Gareth Evans, Manchester, UK
Kari Hemminki, Heidelberg, Germany
Shirley Hodgson, London, UK

Fred Menko, Amsterdam, Netherlands
Gillian Mitchell, Melbourne, Australia
Kenneth Muir, Coventry, UK
Dominique Stoppa-Lyonnet, Paris, France
Hans Vasen, Leiden, Netherlands



BOOKING YOUR OWN CONFERENCE TRAVEL IS EASY AS ABC

WITH THE GLOBAL
ONLINE BOOKING TOOL
FROM STAR ALLIANCE
CONVENTIONS PLUS

No matter where you are travelling from, the Star Alliance™ network offers you a wide choice of flights to ESMO 2014 in Madrid.

And with over 21,900 flights a day to 1,329 destinations across 195 countries, our 28 member airlines extend the same choice to any future conferences you are planning to attend.

You can also save money when you book your flights. Simply quote the Convention Code SK07A03 and you plus one travelling companion will receive a special discount. Better still, no matter which Star Alliance member airline's frequent flyer programme you belong to, you can earn and redeem miles across all 28 airlines.

For more information, or to join the airline network that offers you more choice wherever your conferences take you, simply go to www.staralliance.com/conventionsplus

ADRIA

AEGEAN

AIR CANADA

AIR CHINA

AIR NEW ZEALAND

ANA

ASIANA AIRLINES

Austrian

Avianca

brussels airlines

Copa Airlines

CROATIA AIRLINES

EGYPTAIR

Ethiopian

EVA AIR

LOT POLISH AIRLINES

Lufthansa

Scandinavian Airlines

Shenzhen Airlines

SINGAPORE AIRLINES

SOUTH AFRICAN AIRWAYS

SWISS

TAM

TAP PORTUGAL

THAI

TURKISH AIRLINES

UNITED

U.S. AIRWAYS

www.staralliance.com

Information correct as of 06/2013

STAR ALLIANCE
THE WAY THE EARTH CONNECTS



GASTROINTESTINAL TUMOURS

Saturday, 27 September 2014

11:00/12:30 EDUCATIONAL SESSION **Clinical impact of tumour biology in the management of oesophago-gastric cancer**

Chair: Florian Lordick, Leipzig, Germany

Co-Chair: Fernando Rivera Herrero, Madrid, Spain

Should locally advanced adenocarcinoma of the oesophagus and of the gastroesophageal junction (GEJ) be managed in the same way?

Michael Stahl, Essen, Germany

Surgery: Does response to preoperative therapy modify the extension of surgical resection? When is salvage surgery indicated?

Arnulf Hölscher, Cologne, Germany

Novel targets in the treatment of advanced gastric cancer: What exists already and what comes next?

Florian Lordick, Leipzig, Germany

14:15/15:45 EDUCATIONAL SESSION **Optimising the treatment of colorectal cancer**

Chair: Richard Adams, Cardiff, UK

Co-Chair: to be announced

Are there any useful tools when deciding about adjuvant chemotherapy?

Richard Adams, Cardiff, UK

How to select first line chemotherapy in metastatic colorectal cancer

Claus-Henning Koehne, Oldenburg, Germany

Optimising biomarkers based management beyond KRAS

Sabine Tejpar, Leuven, Belgium

16:00/17:30 EDUCATIONAL SESSION **A multidisciplinary approach to locoregionally advanced rectal cancer**

Chair: Robert Glynne-Jones, Northwood, UK

Co-Chair: Eduardo Diaz Rubio, Madrid, Spain

Radiotherapy: Which type and for whom?

Robert Glynne-Jones, Northwood, UK

Neoadjuvant and adjuvant chemotherapy: Is there a standard of care or not yet?

Andrés Cervantes, Valencia, Spain

Is there still room for improvement in surgery for locoregionally advanced rectal cancer?

Cornelis van de Velde, Leiden, Netherlands

Sunday, 28 September 2014

08:00/09:00 PATIENT CASES **Challenges in oligometastatic disease: Ways towards long-term survival of metastatic colorectal cancer**

Co-Chairs: Theo Ruers, Amsterdam, Netherlands and

Alberto Sobrero, Genoa, Italy

Irresectable liver metastases: What do local ablative treatments contribute?

Theo Ruers, Amsterdam, Netherlands

What drives long-term survival with systemic treatment?

Alberto Sobrero, Genoa, Italy

Discussion

11:00/12:30 EDUCATIONAL SESSION (REPETITION) **A multidisciplinary approach to locoregionally advanced rectal cancer**

Chair: Robert Glynne-Jones, Northwood, UK

Co-Chair: Eduardo Eduardo Diaz Rubio, Madrid, Spain

Radiotherapy: Which type and for whom?

Robert Glynne-Jones, Northwood, UK

Neoadjuvant and adjuvant chemotherapy: Is there a standard of care or not yet?

Andrés Cervantes, Valencia, Spain

Is there still room for improvement in surgery for locoregionally advanced rectal cancer?

Cornelis van de Velde, Leiden, Netherlands

14:15/15:45 SPECIAL SYMPOSIUM **Advances in precision medicine of metastatic colorectal cancer**

Chair: Will Steward, Leicester, UK

Co-Chair: Thomas Seufferlein, Ulm, Germany

Introduction

Thomas Seufferlein, Ulm, Germany

New molecular classification of colorectal cancer

Krisztian Homicsko, Lausanne, Switzerland

Emerging druggable targets in colorectal cancer

Federica Di Nicolantonio, Candiolo, Italy

Signal transduction inhibitors and pipeline drugs

Josep Tabernero, Barcelona, Spain

Immunotherapy and vaccines

Pierpaolo Corrales, Siena, Italy

Liquid biopsies and "on treatment" markers

Gerald Prager, Vienna, Austria

Conclusions and clinical perspectives

Will Steward, Leicester, UK

SCIENTIFIC COMMITTEE (COLORECTAL)

Dirk Arnold, Freiburg, Germany, Chair

Eduardo Díaz-Rubio, Madrid, Spain
Federica Di Nicolantonio, Candiolo, Italy
Axel Grothey, Rochester, MN, USA
Thomas Grünberger, Vienna, Austria
Corrie Marijnen, Leiden, Netherlands
Per Pfeiffer, Odense, Denmark

Gerald Prager, Vienna, Austria
Thomas Seufferlein, Ulm, Germany
Matthew Seymour, Leeds, UK
Alberto Sobrero, Genoa, Italy
Sabine Tejpar, Leuven, Belgium
Christophe Tournigand, Créteil, France

Monday, 29 September 2014

10:30/11:30 MULTIDISCIPLINARY INTERACTIVE SESSION (MIS) **Locally advanced pancreatic cancer**

Chair: Eric Van Cutsem, Leuven, Belgium
Co-Chair: Bengt Glimelius, Uppsala, Sweden

Radiation oncology
Bengt Glimelius, Uppsala, Sweden

Medical oncology
Eric Van Cutsem, Leuven, Belgium

Discussion

11:45/12:45 MULTIDISCIPLINARY INTERACTIVE SESSION (MIS) **Sequence of treatment in colorectal cancer with synchronous metastases**

Chair: Bernard Nordlinger, Boulogne, France
Co-Chair: Gunnar Folprecht, Dresden, Germany

Surgery
Bernard Nordlinger, Boulogne, France

Medical oncology
Gunnar Folprecht, Dresden, Germany

Discussion

11:45/12:45 PATIENT CASES **Integrating systemic and locoregional therapies in a patient with advanced hepatocellular carcinoma (HCC)**

Co-Chairs: Riccardo Lencioni, Pisa, Italy and
Chris Verslype, Leuven, Belgium

Systemic therapy
Chris Verslype, Leuven, Belgium

Locoregional therapy
Riccardo Lencioni, Pisa, Italy

Discussion

14:15/15:15 MULTIDISCIPLINARY INTERACTIVE SESSION (MIS) **Multidisciplinary management of peritoneal carcinomatosis**

Chair: Dominique Elias, Villejuif, France
Co-Chair: Cornelis Punt, Amsterdam, Netherlands

Surgery
Dominique Elias, Villejuif, France

Medical oncology
Cornelis Punt, Amsterdam, Netherlands

Discussion

14:15/15:45 EDUCATIONAL SESSION (REPETITION) **Optimising the treatment of colorectal cancer**

Chair: Richard Adams, Cardiff, UK
Co-Chair: to be announced

Are there any useful tools when deciding about adjuvant chemotherapy?

Richard Adams, Cardiff, UK

How to select first line chemotherapy in metastatic colorectal cancer

Claus-Henning Koehne, Oldenburg, Germany

Optimising biomarkers based management beyond KRAS
Sabine Tejpar, Leuven, Belgium

16:00/17:30 SPECIAL SYMPOSIUM **Towards personalised medicine in gastric, pancreatic and liver cancer: From "omics" research to treatment**

Chair: Erika Martinelli, Naples, Italy
Co-Chair: Michel Ducreux, Villejuif, France

Introduction
Michel Ducreux, Villejuif, France

What are the new tools available?
Peter Schirmacher, Heidelberg, Germany

Hepatocellular carcinoma (HCC)
Augusto Villanueva, London, UK

Pancreatic cancer
Manuel Hidalgo, Madrid, Spain

Gastric cancer
Patrick Tan, Singapore

Conclusions and clinical perspectives
Erika Martinelli, Naples, Italy

SCIENTIFIC COMMITTEE (NON-COLORECTAL)

Andrés Cervantes, Valencia, Spain, Chair

Regina Beets-Tan, Maastricht, Netherlands
Fátima Carneiro, Porto, Portugal
Thierry Conroy, Vandoeuvre-les-Nancy, France
Michel Ducreux, Villejuif, France
Karin Haustermans, Leuven, Belgium
Florian Lordick, Leipzig, Germany

Teresa Macarulla, Barcelona, Spain
Erika Martinelli, Naples, Italy
Fernando Rivera, Santander, Spain
Juan Valle, Manchester, UK
Chris Verslype, Leuven, Belgium

GENITOURINARY TUMOURS

Saturday, 27 September 2014

08:00/ 09:00 **CHALLENGE YOUR EXPERT (CYE)**
Management of relapsed germ cell tumours
Speaker: Joerg Beyer, Zurich, Switzerland

08:00/ 09:00 **PATIENT CASES**
Multimodal treatment approaches in bladder cancer
*Co-Chairs: Thierry Lebre, Suresnes, France;
Nicholas James, Birmingham, UK and David Solit, New York, NY
US*
The role of surgery in advanced bladder cancer
Thierry Lebre, Suresnes, France
Precision drug treatment for bladder cancer
David Solit, New, York, NY, US
Is surgery always necessary?
Nicholas James, Birmingham, UK
Discussion

14:00/ 15:45 **SPECIAL SYMPOSIUM**
Precision medicine in prostate cancer
*Chair: Mark Rubin, New York, NY, US
Co-Chair: Eleni Efsthathiou, Athens, Greece*
Introduction
Eleni Efsthathiou, Athens, Greece
Prostate carcinogenesis: What have we learnt from next generation sequencing?
Levi A. Garraway, Boston, MA, US
Do we need a new taxonomy for prostate cancer?
Mark Rubin, New York, NY, US
Will circulating biomarkers help to deliver precision medicine?
David Olmos, Madrid, Spain
Immunotherapy for prostate cancer?
Charles Drake, Baltimore, MD, US
Where next for precision medicine for prostate cancer?
Eleni Efsthathiou, Athens, Greece
Conclusions and clinical perspectives
Mark Rubin, New York, NY, US

16:00/ 17:30 **EDUCATIONAL SESSION**
Update in genitourinary oncology
*Chair: Bernard Escudier, Villejuif, France
Co-Chair: Ian Tannock, Toronto, ON, Canada*
Optimal sequence of treatment for metastatic prostate cancer
Cora Sternberg, Rome, Italy
How to deal with unresectable and inoperable bladder cancer
Maria de Santis, Vienna, Austria
Treatment of metastatic renal cell carcinoma (RCC): Present and future
Bernard Escudier, Villejuif, France

Sunday, 28 September 2014

08:00/ 09:00 **CYE (REPETITION)**
Management of relapsed germ cell tumours
Speaker: Joerg Beyer, Zurich, Switzerland

11:00/ 12:30 **EDUCATIONAL SESSION (REPETITION)**
Update in genitourinary oncology
*Chair: Bernard Escudier, Villejuif, France
Co-Chair: Ian Tannock, Toronto, ON, Canada*
Optimal sequence of treatment for metastatic prostate cancer
Cora Sternberg, Rome, Italy
How to deal with unresectable and inoperable bladder cancer
Maria de Santis, Vienna, Austria
Treatment of metastatic renal cell carcinoma (RCC): Present and future
Bernard Escudier, Villejuif, France

Monday, 29 September 2014

08:00/ 09:00 **PATIENT CASES**
Treatment of castration-resistant prostate cancer (CRPC) in special situations
*Co-Chairs: Gerhardt Attard, Surrey, UK,
Anna Falanga, Bergamo, Italy and Stephane Oudard, Paris, France*
Treating elderly patients
Stephane Oudard, Paris, France
When is prostate cancer truly androgen independent?
Gerhardt Attard, Surrey, UK
Bone marrow carcinosis and disseminated intravascular coagulation (DIC)
Anna Falanga, Bergamo, Italy
Discussion

09:15/ 10:45 **SPECIAL SYMPOSIUM**
Beyond tumour heterogeneity: New pathways in kidney cancer
*Chair: Viktor Grünwald, Hannover, Germany
Co-Chair: Cora Sternberg, Rome, Italy*
Introduction
Cora Sternberg, Rome, Italy
Molecular classification of kidney cancer
Andrew Futreal, Houston, TX, US
Precision medicine in kidney cancer and clinical trial designs
James Larkin, London, UK
Immunotherapy: Myth or reality?
David McDermott, Boston, MA, US
New drugs and new targets (phase I)
Emiliano Calvo, Madrid, Spain
Conclusions and clinical perspectives
Viktor Grünwald, Hannover, Germany

SCIENTIFIC COMMITTEE (PROSTATE)

Eleni Efstathiou, Athens, Greece, Chair

Gerhardt Attard, Sutton, UK
Karim Fizazi, Villejuif, France
Silke Gillissen, St. Gallen, Switzerland
Axel Heidenreich, Aachen, Germany
David Olmos, Madrid, Spain
Stephane Oudard, Paris, France

Chris Parker, Sutton, UK
Mark Rubin, New York, NY, US
Jack Schalken, Nijmegen, Netherlands
Avishay Sella, Zerifin, Israel
Anders Widmark, Umeå, Sweden

SCIENTIFIC COMMITTEE (NON-PROSTATE)

James Larkin, London, UK, Chair

Michael Aitchison, Glasgow, UK
Axel Bex, Amsterdam, Netherlands
Emiliano Calvo, Madrid, Spain
Maria De Santis, Vienna, Austria
Bernard Escudier, Villejuif, France
Viktor Grünwald, Hannover, Germany

Nicholas James, Birmingham, UK
Arnaud Mejean, Paris, France
Gerald Mickisch, Bremen, Germany
Manuela Schmidinger, Vienna, Austria
Cora Sternberg, Rome, Italy

Saturday, 27 September 2014

08:00/ 09:00 **CHALLENGE YOUR EXPERT (CYE)**
Medical treatment for advanced endometrial cancer
Speaker: Cristiana Sessa, Bellinzona, Switzerland

14:15/ 15:45 **EDUCATIONAL SESSION**
Ovarian cancer
Chair: Antonio Gonzalez Martin, Madrid, Spain
Co-Chair: Nicoletta Colombo, Milan, Italy
Antiangiogenic therapy: Where in the disease pathway and which patients?
Antonio Gonzalez Martin, Madrid, Spain
How to recognise and treat low grade tumours
Jonathan Ledermann, London, UK
Treatment for relapsing patients
Sandro Pignata, Naples, Italy

Sunday, 28 September 2014

08:00/ 09:00 **CYE (REPETITION)**
Medical treatment for advanced endometrial cancer
Speaker: Cristiana Sessa, Bellinzona, Switzerland

09:30/ 10:30 **MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)**
Management of localised endometrial cancer
Chair: Carien L. Creutzberg, Leiden, Netherlands
Co-Chair: Mansoor Mirza, Copenhagen, Denmark
Radiotherapy
Carien L. Creutzberg, Leiden, Netherlands
Clinical oncology
Mansoor Mirza, Copenhagen, Denmark
Discussion

11:00/ 12:30 **SPECIAL SYMPOSIUM**
Targeted therapy in gynaecological cancer
Chair: Andres Poveda, Valencia, Spain
Co-Chair: Eric Pujade-Lauraine, Paris, France
Introduction
Eric Pujade-Lauraine, Paris, France
Emerging molecular targets in gynaecological cancer
David Huntsman, Vancouver, BC, Canada
The impact of targeted therapy in cervical and endometrial cancer
Ana Oaknin, Barcelona, Spain
Targeted therapy of ovarian cancer: Beyond angiogenesis
Nicoletta Colombo, Milan, Italy
The coming decade
Michael Bookman, Tucson, AZ, US
Conclusions and clinical perspectives
Andres Poveda, Valencia, Spain

14:15/ 15:45 **EDUCATIONAL SESSION (REPETITION)**
Ovarian cancer
Chair: Antonio Gonzalez Martin, Madrid, Spain
Co-Chair: Nicoletta Colombo, Milan, Italy
Antiangiogenic therapy: Where in the disease pathway and which patients?
Antonio Gonzalez Martin, Madrid, Spain
How to recognise and treat low grade tumours
Jonathan Ledermann, London, UK
Treatment for relapsing patients
Sandro Pignata, Naples, Italy

Monday, 29 September 2014

08:00/ 09:00 **PATIENT CASES**
Primary surgery or neoadjuvant chemotherapy for ovarian cancer: How should we select the patients?
Co-Chairs: Charles Gourley, Edinburgh, UK;
Christian Marth, Innsbruck, Austria and
Isabelle Ray-Coquard, Lyon, France
The role of upfront surgery
Christian Marth, Innsbruck, Austria
Best neo-adjuvant therapy: Options for selected patients
Isabelle Ray-Coquard, Lyon, France
Is there a molecular analysis that can help us define a subgroup of patients?
Charles Gourley, Edinburgh, UK
Discussion

SCIENTIFIC COMMITTEE

Andres Poveda, Valencia, Spain, Chair

Michael Bookman, Tucson, AZ, US
Antonio González Martin, Madrid, Spain
Philipp Harter, Essen, Germany
Jonathan Ledermann, London, UK
Christian Marth, Innsbruck, Austria
Mansoor Mirza, Copenhagen, Denmark

José Palacios Calvo, Madrid, Spain
Timothy Perren, Leeds, UK
Sandro Pignata, Naples, Italy
Eric Pujade-Lauraine, Paris, France
Isabelle Ray-Coquard, Lyon, France

Saturday, 27 September 2014

- 14:15/ 15:45 **SPECIAL SYMPOSIUM**
Targeting signalling pathways in haematological malignancies: Are we close to the end of histopathological classification and the chemotherapy era?
Chair: Andreas Rosenwald, Würzburg, Germany
Co-Chair: Faith Davies, Sutton, UK
 Introduction: Is a purely biological classification of lymphoma possible?
Faith Davies, Sutton, UK
 Targeting kinases and relevance in B-cell lymphomas (BCL)
Ingo Ringshausen, Munich, Germany
 Targeting the BCL-2 pathway
Anthony Letai, Boston, MA, US
 Targeting the cyclins
Paolo Ghia, Milan, Italy
 Translating genetics into clinical care
Thorsten Zenz, Heidelberg, Germany
 Conclusions: Is this the end of chemotherapy in lymphoma?
Andreas Rosenwald, Würzburg, Germany

Monday, 29 September 2014

- 09:15/ 10:15 **PATIENT CASES**
Imaging decisions in haematological malignancies
Co-Chairs: Josee Zijlstra, Amsterdam, Netherlands and Christina Messiou, Surrey, UK
 Lymphoma: What to do and when?
Josee Zijlstra, Amsterdam, Netherlands
 Myeloma: What to do and when?
Christina Messiou, Surrey, UK
 Discussion
-
- 11:00/ 12:30 **JOINT SYMPOSIUM: ESMO - EANM**
Impact of molecular imaging on management of lymphoma
Co-Chairs: Michele Ghielmini, Bellinzona, Switzerland and Wim Oyen, Nijmegen, Netherlands
 Introduction
Wim Oyen, Nijmegen, Netherlands
 PET-based decisions in Hodgkin's lymphoma
Martin Hutchings, Copenhagen, Denmark
 PET-based decisions in non Hodgkin's lymphoma
Josee Zijlstra, Amsterdam, Netherlands
 Potential and pitfalls in PET-imaging of lymphoma
To be announced
 PET-based response criteria in lymphoma : Current status and future directions
Michel Meignan, Créteil, France
 Conclusions
Michele Ghielmini, Bellinzona, Switzerland
-
- 16:00/ 17:30 **EDUCATIONAL SESSION**
Major lymphoma subtypes in the elderly
Chair: Martin Dreyling, Munich, Germany
Co-Chair: Michele Ghielmini, Bellinzona, Switzerland
 Diffuse large cell lymphoma: 8x R-CHOP 21: Is there one standard therapy for all patients?
Peter Johnson, Southampton, UK
 Follicular lymphoma: Is it a boring disease?
Martin Dreyling, Munich, Germany
 Chronic lymphocytic leukemia (CLL): Is treatment the same as in younger patients?
Michael Hallek, Cologne, Germany

SCIENTIFIC COMMITTEE

Faith Davies, Sutton, UK, Chair

Peter Campbell, Cambridge, UK
 Enrico Derenzini, New York, NY, US
 Paolo Ghia, Milan, Italy
 Enrico Ocio, Salamanca, Spain
 Gert Ossenkoppele, Amsterdam, Netherlands
 Mariano Provencio, Madrid, Spain

Ingo Ringshausen, Munich, Germany
 Andreas Rosenwald, Würzburg, Germany
 Evangelos Terpos, Athens, Greece
 Elena Zamagni, Bologna, Italy
 Thorsten Zenz, Heidelberg, Germany

Saturday, 27 September 2014

08:00/ 09:00 **CHALLENGE YOUR EXPERT (CYE)**
Larynx preservation: How should we decide the best treatment?

Speaker: Jean-Louis Lefebvre, Lille, France

11:00/ 12:30 **SPECIAL SYMPOSIUM**
Personalised medicine in head and neck cancer

Chair: Sandrine Faivre, Clichy, France

Co-Chair: Juan J. Grau, Barcelona, Spain

Introduction

Juan J. Grau, Barcelona, Spain

New targets in squamous cell carcinoma

Jean-Pascal Machiels, Brussels, Belgium

New targets in salivary gland cancer

Andrew Futreal, Houston, TX, US

Immunotherapy for head and neck cancer

Erik Hooijberg, Amsterdam, Netherlands

Next generation technology for next generation trials

Christophe Le Tourneau, Paris, France

Conclusion and clinical perspectives

Sandrine Faivre, Clichy, France

Sunday, 28 September 2014

08:00/ 09:00 **CYE (REPETITION)**
Larynx preservation: How should we decide the best treatment?

Speaker: Jean-Louis Lefebvre, Lille, France

11:00/ 12:00 **MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)**
Locally advanced nasopharyngeal carcinoma

Chair: Lisa Licitra, Milan, Italy

Co-Chair: Jean Bourhis, Lausanne, Switzerland

Medical oncology

Lisa Licitra, Milan, Italy

Radiotherapy

Jean Bourhis, Lausanne, Switzerland

Discussion

14:30/ 15:30 **PATIENT CASES**
Treatment of medullary thyroid cancer (MTC)

Co-Chairs: Jaume Capdevila, Barcelona, Spain and

Sophie Leboulleux, Villejuif, France

Sub-classification and treatment of MTC

Sophie Leboulleux, Villejuif, France

Practical management of tyrosine-kinase inhibitor (TKI)

Jaume Capdevila, Barcelona, Spain

Discussion

SCIENTIFIC COMMITTEE

Sandrine Faivre, Clichy, France, Chair

Jean Bourhis, Lausanne, Switzerland

Andreas Dietz, Leipzig, Germany

Cai Grau, Aarhus, Denmark

Juan José Grau, Barcelona, Spain

Kevin Harrington, London, UK

Florence Huguet, Paris, France

Gabriela Kornek, Vienna, Austria

Christophe Le Tourneau, Paris, France

Lisa Licitra, Milan, Italy

Jean-Pascal Machiels, Brussels, Belgium

Amanda Psyrri, Athens, Greece

Saturday, 27 September 2014

- 11:00/12:30 JOINT SYMPOSIUM: ESMO - ESP
Tissue markers for immuno-oncology**
*Co-Chairs: Fatima Carneiro, Porto, Portugal and
Fortunato Ciardiello, Naples, Italy*
Introduction
Fortunato Ciardiello, Naples, Italy
The importance of the preanalytical phase (the proper handling of specimens from site of biopsy to pathology lab, fixation etc) for immunohistochemistry
To be announced
How to quantify immunohistochemical slides
To be announced
Importance of external quality assessment in immuno-oncology
To be announced
What the oncologist needs from the pathologist
To be announced
Conclusions
Fatima Carneiro, Porto, Portugal

- 13:00/13:45 KEYNOTE LECTURE
Delivering precision immunotherapy**
Chair: George Coukos, Lausanne, Switzerland
Speaker: Carl June, Philadelphia, PA, US

Sunday, 28 September 2014

- 14:15/15:45 SPECIAL SESSION
Evasion, activation and manipulation of the cancer immuno response**
Chair: Sjoerd van der Burg, Leiden, Netherlands
Co-Chair: Inge Marie Svane, Herlev, Denmark
Introduction
Sjoerd van der Burg, Leiden, Netherlands
Overcoming immune evasion
Daniel Speiser, Lausanne, Switzerland
Precision medicine in immunotherapy
George Coukos, Lausanne, Switzerland
Building rational combinations in immunotherapy
Michele Maio, Siena, Italy
Clinical interpretation of response with immunotherapy
John Haanen, Amsterdam, Netherlands
Conclusions and clinical perspectives
Inge Marie Svane, Herlev, Denmark

- 16:00/17:30 EDUCATIONAL SESSION
Fundamental principles of cancer immunotherapy:
What the clinician needs to know**
Chair: Suzy Scholl, Paris, France
Co-Chair: Ulrich Keilholz, Berlin, Germany
Fundamental principles of antitumour immune response: A summary for the clinician
Suzy Scholl, Paris, France
Fundamental mechanisms of tumour immune evasion: A summary for the clinician
Sjoerd van der Burg, Leiden, Netherlands
How therapeutic immunomodulation can restore antitumour immunity: From theory to practice
Mario Sznol, New Haven, CT, US

Monday, 29 September 2014

- 09:00/10:30 SPECIAL SYMPOSIUM
Activating immune response to cancer**
Chair: Michele Maio, Siena, Italy
Co-Chair: Suzy Scholl, Paris, France
Introduction
Suzy Scholl, Paris, France
Tumour infiltrating lymphocytes (TIL) and their use in therapy
Inge Marie Svane, Herlev, Denmark
Adoptive therapy with engineered T-cells
Carl June, Philadelphia, PA, US
New developments in clinical vaccinations
Ulrich Keilholz, Berlin, Germany
Rational combinations in cancer immunotherapy
Ignacio Melero, Pamplona, Spain
Conclusions and clinical perspectives
Michele Maio, Siena, Italy
- 14:30/15:30 PATIENT CASES
Immunotherapy in clinical practice**
*Co-Chairs: Antoni Ribas, Los Angeles, CA, US and
Dirk Schadendorf, Essen, Germany*
Challenges in the assessment of response to cancer immunotherapy
Antoni Ribas, Los Angeles, CA, US
Management of toxicity during immunotherapy
Dirk Schadendorf, Essen, Germany
Discussion

SCIENTIFIC COMMITTEE

George Coukos, Lausanne, Switzerland, Chair

Hinrich Abken, Cologne, Germany
Luis de la Cruz Merino, Seville, Spain
John Haanen, Amsterdam, Netherlands
Robert Hawkins, Manchester, UK
Ulrich Keilholz, Berlin, Germany

Michele Maio, Siena, Italy
Ignacio Melero, Pamplona, Spain
Suzy Scholl, Paris, France
Inge-Marie Svane, Copenhagen, Denmark
Sjoerd van der Burg, Leiden, Netherlands

LUNG CANCER AND OTHER THORACIC MALIGNANCIES

Saturday, 27 September 2014

- 08:00/ 09:00 **PATIENT CASES**
Therapeutic challenges in oncogene addicted lung cancers
Co-Chairs: Silvia Novello, Orbassano, Italy and Ken O'Byrne, Brisbane, Australia
 A case of EGFR mutation in squamous cell carcinoma
Silvia Novello, Orbassano, Italy
 A ROS1 translocated NSCLC patient
Ken O'Byrne, Brisbane, Australia
 Discussion
-
- 09:15/ 10:45 **EDUCATIONAL SESSION**
Systemic treatment of metastatic NSCLC
Chair: Benjamin Besse, Villejuif, France
Co-Chair: Lucio Crinò, Perugia, Italy
 Non-oncogenic addicted NSCLC patients: What is the best approach?
Benjamin Besse, Villejuif, France
 Oncogenesis addiction, biomarkers: Who should be tested and when?
Pasi Jänne, Boston, MA, US
 How do we define progression and what is to be done?
Anne-Marie Dingemans, Maastricht, Netherlands
-
- 11:00/ 12:30 **EDUCATIONAL SESSION**
Clinical issues in metastatic NSCLC
Chair: Tony S.K. Mok, Hong Kong, China
Co-Chair: Jean-Yves Douillard, St. Herblain, France
 Is there anything new in squamous cells?
Wilfried Eberhardt, Essen, Germany
 The best approach to oligometastatic NSCLC
Jaroslav Kuzdza, Krakow, Poland
 Optimal sequence of administration for targeted agents and chemotherapy
Tony S.K. Mok, Hong Kong, China
-
- 14:30/ 15:30 **PATIENT CASES**
Challenging cases of oligometastatic NSCLC
Co-Chairs: Umberto Ricardi, Turin, Italy and Michael Thomas, Ulm, Germany
 An EGFR mutated patient with a right/left -sided located T3N0 non-squamous cell lung cancer and a solitary right/left adrenal gland metastasis
Michael Thomas, Ulm, Germany
 A patient with a right upper lobe peripherally located T1b adenocarcinoma with a bone metastasis in the left rib 9 and in dorsal vertebra 4
Umberto Ricardi, Turin, Italy
 Discussion

Sunday, 28 September 2014

- 09:00/ 10:30 **EDUCATIONAL SESSION (REPETITION)**
Systemic treatment of metastatic NSCLC
Chair: Benjamin Besse, Villejuif, France
Co-Chair: Lucio Crinò, Perugia, Italy
 Non-oncogenic addicted NSCLC patients: What is the best approach?
Benjamin Besse, Villejuif, France
 Oncogenesis addiction, biomarkers: Who should be tested and when?
Pasi Jänne, Boston, MA, US
 How do we define progression and what is to be done?
Anne-Marie Dingemans, Maastricht, Netherlands
-
- 11:00/ 12:30 **EDUCATIONAL SESSION (REPETITION)**
Clinical issues in metastatic NSCLC
Chair: Tony S.K. Mok, Hong Kong, China
Co-Chair: Jean-Yves Douillard, St. Herblain, France
 Is there anything new in squamous cells?
Wilfried Eberhardt, Essen, Germany
 The best approach to oligometastatic NSCLC
Jaroslav Kuzdza, Krakow, Poland
 Optimal sequence of administration for targeted agents and chemotherapy
Tony S.K. Mok, Hong Kong, China
-
- 14:15/ 15:15 **MULTIDISCIPLINARY INTERACTIVE SESSION (MIS)**
Management of brain metastasis: Surgery vs radiation vs late intervention
Chair: Dirk De Ruysscher, Leuven, Belgium
Co-Chair: Lucio Crinò, Perugia, Italy
 Medical oncology
Lucio Crinò, Perugia, Italy
 Radiotherapy
Dirk De Ruysscher, Leuven, Belgium
 Discussion

SCIENTIFIC COMMITTEE (NSCLC, EARLY STAGE, SCLC AND OTHER THORACIC MALIGNANCIES)

Johan Vansteenkiste, Leuven, Belgium, Chair

Benjamin Besse, Villejuif, France
 Dirk De Ruysscher, Leuven, Belgium
 Wilfried Eberhardt, Essen, Germany
 Eric Lim, London, UK
 Celine Mascaux, Toronto, ON, Canada
 Tetsuya Mitsudomi, Osaka-Sayama, Japan

Gaetano Rocco, Naples, Italy
 Giorgio Scagliotti, Orbassano, Italy
 Philipp Schnabel, Heidelberg, Germany
 Suresh Senan, Amsterdam, Netherlands
 Giulia Veronesi, Milan, Italy

Monday, 29 September 2014

08:00/09:00 **CHALLENGE YOUR EXPERT (CYE)**
SCLC: Current approaches and the role of radiotherapy (thoracic and PCI) in stage IV disease
Speaker: Thierry Le Chevalier, Villejuif, France

09:00/10:30 **SPECIAL SYMPOSIUM**
The evolving role of systemic treatment in advanced NSCLC

Chair: Jean-Charles Soria, Villejuif, France
Co-Chair: Ken O'Byrne, Brisbane, Australia

Introduction

Ken O'Byrne, Brisbane, Australia

Reclassifying lung cancer and molecular diagnostic
Ramaswamy Govindan, St. Louis, MO, US

Targeting tumour addiction

Rafal Dziadziuszko, Gdansk, Poland

Secondary resistance to systemic treatment

Egbert Smit, Amsterdam, Netherlands

Immunotherapy: Current status

Martin Reck, Grosshansdorf, Germany

Conclusions and clinical perspectives

Jean-Charles Soria, Villejuif, France

16:00/17:30 **SPECIAL SYMPOSIUM**
Diagnostic and therapeutic challenges in thoracic malignancies

Chair: Johan Vansteenkiste, Leuven, Belgium

Co-Chair: Suresh Senan, Amsterdam, Netherlands

Introduction

Suresh Senan, Amsterdam, Netherlands

Optimal assessment of an additional lung nodule in a patient with potential for cure

Christophe Dooms, Leuven, Belgium

What is the place of less invasive surgery in lung cancer?

Giulia Veronesi, Milan, Italy

Stereotactic ablative radiotherapy in early stage NSCLC

Suresh Senan, Amsterdam, Netherlands

Defining the role of targeted therapies in early stage NSCLC

Solange Peters, Lausanne, Switzerland

Conclusions and clinical perspectives

Johan Vansteenkiste, Leuven, Belgium

Tuesday, 30 September 2014

08:00/09:00 **CYE (REPETITION)**
SCLC: Current approaches and the role of radiotherapy (thoracic and PCI) in stage IV disease
Speaker: Thierry Le Chevalier, Villejuif, France

SCIENTIFIC COMMITTEE (NSCLC, METASTATIC)

Solange Peters, Lausanne, Switzerland, Chair

Alex A. Adjei, Buffalo, NY, US
 Lucio Crinò, Perugia, Italy
 Rafal Dziadziuszko, Gdansk, Poland
 Keith Kerr, Aberdeen, UK
 Tony S.K. Mok, Hong Kong, China
 Silvia Novello, Orbassano, Italy

Ken O'Byrne, Brisbane, Australia
 Martin Reck, Grosshansdorf, Germany
 Rafael Rosell, Badalona, Spain
 Egbert Smit, Amsterdam, Netherlands
 James Spicer, London, UK

MELANOMA AND OTHER SKIN TUMOURS

Saturday, 27 September 2014

09:15/ PATIENT CASES

10:15 Immunotherapy or targeted therapy for oncogene addicted melanoma

Co-Chairs: Anna Maria Di Giacomo, Siena, Italy and James Larkin, London, UK

Choice of immunotherapy vs targeted therapy in first line (BRAF)
James Larkin, London, UK

Oncogene addicted brain metastases
Anna Maria Di Giacomo, Siena, Italy

Discussion

11:00/ EDUCATIONAL SESSION

12:30 Skin tumours update

Chair: Jürgen Becker, Graz, Austria

Co-Chair: to be announced

Merkel cell carcinoma

Jürgen Becker, Graz, Austria

Adjuvant treatment of melanoma

Olivier Michielin, Lausanne, Switzerland

Targeted therapy and immunotherapy for melanoma

David Solit, New York, NY, US

16:00/ SPECIAL SYMPOSIUM

17:30 The science behind combinations with immunotherapy in melanoma

Chair: John Haanen, Amsterdam, Netherlands

Co-Chair: Christian Blank, Amsterdam, Netherlands

Introduction

Christian Blank, Amsterdam, Netherlands

The tumour microenvironment as a barrier for immune destruction of cancer

Jürgen Becker, Graz, Austria

Rationale to combine immunotherapy with physical therapy
Kevin Harrington, London, UK

Which systemic therapies should be combined to immunotherapy?

Christian Blank, Amsterdam, Netherlands

Combining immunotherapies

Antoni Ribas, Los Angeles, CA, US

Conclusions and clinical perspectives

John Haanen, Amsterdam, Netherlands

SCIENTIFIC COMMITTEE

Caroline Robert, Villejuif, France, Chair

Paolo Ascierto, Naples, Italy

Jürgen Becker, Graz, Austria

Christian Blank, Amsterdam, Netherlands

Reinhard Dummer, Zurich, Switzerland

Jean-Jacques Grob, Marseille, France

José Antonio López Martín, Madrid, Spain

Richard Marais, Manchester, UK

Grant McArthur, Melbourne, Australia

Olivier Michielin, Lausanne, Switzerland

Mark Middleton, Oxford, UK

Antoni Ribas, Los Angeles, CA, US

Sunday, 28 September 2014

10:30/ 11:30 **PATIENT CASES**
How does one manage rare neuroendocrine malignancies?

Co-Chairs: Piero Ferolla, Perugia, Italy and Alexandria Phan, Houston, TX, US

Malignant bronchial carcinoid tumour
Piero Ferolla, Perugia, Italy

Paraganglioma
Alexandria Phan, Houston, TX, US

Discussion

16:00/ 17:30 **SPECIAL SYMPOSIUM**
Neuroendocrine tumours: The cutting edge and a glimpse into the future

Chair: Ian Chau, Sutton, UK

Co-Chair: Philippe Ruszniewski, Clichy, France

Introduction

Philippe Ruszniewski, Clichy, France

Towards new molecular classification for neuroendocrine tumours

Aldo Scarpa, Verona, Italy

Tools to evaluate tumour response to therapy: Imaging

Marie-Pierre Vullierme, Clichy, France

Tools to evaluate tumour response to therapy: Tissue biomarkers

Tim Meyer, London, UK

Do minimal access and robotic surgery bring benefit to neuroendocrine tumours?

Massimo Falconi, Ancona, Italy

Current landscape and ongoing clinical trials for medical therapy in neuroendocrine tumours

Marianne Pavel, Berlin, Germany

Clinical trial endpoints relevant to patients/society for rare tumours and conclusions

Ian Chau, Sutton, UK

Monday, 29 September 2014

11:00/ 12:30 **EDUCATIONAL SESSION**
Update on all neuroendocrine tumours

Chair: Ian Chau, Sutton, UK

Co-Chair: Alfredo Carrato, Madrid, Spain

Classification and tumour biology

Kjell Öberg, Uppsala, Sweden

Molecular imaging and peptide receptor radionuclide therapy (PRRT)

Lisa Bodei, Milan, Italy

Classical and targeted therapies in GEP-NETs

Ian Chau, Sutton, UK

SCIENTIFIC COMMITTEE

Ian Chau, Sutton, UK, Chair

Massimo Falconi, Ancona, Italy
Ashley Grossman, Headington, UK
Dik Kwekkeboom, Rotterdam, Netherlands
Steven Libutti, New York, NY, US
Kjell Öberg, Uppsala, Sweden

Marianne Pavel, Berlin, Germany
Alexandria Phan, Houston, TX, US
Guido Rindi, Rome, Italy
Philippe Ruszniewski, Clichy, France
Britt Skogseid, Uppsala, Sweden

Saturday, 27 September 2014

- 16:00/ 17:00 **PATIENT CASES**
Avoiding overdiagnosis and overtreatment in cancer screening: Assessing the role of personalised screening
Co-Chairs: Harry de Koning, Rotterdam, Netherlands; Silvia de Sanjose, L'Hospitalet de Llobregat, Spain and Nereo Segnan, Turin, Italy
Precision medicine in cancer prevention: From genomic to stratified, population based cancer screening
Nereo Segnan, Turin, Italy
Personalised versus organised approaches to screening of cervical cancer: Can we fit both?
Silvia de Sanjose, L'Hospitalet de Llobregat, Spain
Pulmonary nodules and CT-lung cancer screening
Harry de Koning, Rotterdam, Netherlands
Discussion

Monday, 29 September 2014

- 14:15/ 15:45 **SPECIAL SYMPOSIUM**
The impact on health services from personalised targeted therapies
Chair: Josep M. Borras, Barcelona, Spain
Co-Chair: Tit Albreht, Ljubljana, Slovenia
Introduction
Tit Albreht, Ljubljana, Slovenia
Confronting health services: Targeting the baby boom
Valery Lemmens, Eindhoven, Netherlands
Budget impact vs cost effectiveness: Implications for personalised cancer therapies
Yolande Lievens, Ghent, Belgium
Evolution of pricing and reimbursement structure of cancer therapies in Europe
Richard Sullivan, London, UK
Personalised medicine in National Cancer Plans: How can innovation be translated into policy?
Jose Maria Martin Moreno, Valencia, Spain
Conclusions and clinical perspectives
Josep M. Borras, Barcelona, Spain

SCIENTIFIC COMMITTEE

Josep Maria Borras, Barcelona, Spain, Chair

Tit Albreht, Ljubljana, Slovenia
Freddie Bray, Lyon, France
Jack Cuzick, London, UK
Harry de Koning, Rotterdam, Netherlands
Silvia de Sanjose, L'Hospitalet de Llobregat, Spain

Silvano Gallus, Milan, Italy
Valery Lemmens, Eindhoven, Netherlands
Yolande Lievens, Ghent, Belgium
Jose M. Martin-Moreno, Valencia, Spain
Nereo Segnan, Turin, Italy

Saturday, 27 September 2014

09:00/10:30 **EDUCATIONAL SESSION**
Biology must guide the treatment in sarcoma
Chair: Silvia Stacchiotti, Milan, Italy
Co-Chair: Jean-Yves Blay, Lyon, France
 Sarcoma pathology for clinicians
A. Paolo dei Tos, Treviso, Italy
 Could medical treatment be histology guided?
Silvia Stacchiotti, Milan, Italy
 Gastrointestinal stromal tumours (GIST)
Sebastian Bauer, Essen, Germany

Sunday, 28 September 2014

16:00/17:00 **PATIENT CASES**
The management of isolated lung metastases from soft tissue sarcomas (STS)
Co-Chairs: Axel Le Cesne, Villejuif, France;
Aisha Miah, London, UK and Ugo Pastorino, Milan, Italy
 Surgery: Why and when?
Ugo Pastorino, Milan, Italy
 Systemic treatment for a patient with isolated lung metastases:
 What is the current standard?
Axel Le Cesne, Villejuif, France
 The sense and non-sense of radiotherapy and radiofrequency
 ablation to control isolated lung metastases
Aisha Miah, London, UK
 Discussion

Monday, 29 September 2014

11:00/12:30 **SPECIAL SYMPOSIUM**
Controversies in the neo-adjuvant treatment of localised soft tissue sarcomas (STS)
Chair: Alessandro Gronchi, Milan, Italy
Co-Chair: Stefan Sleijfer, Rotterdam, Netherlands
 Introduction: Induction therapy in localised STS: For whom and with what?
Stefan Sleijfer, Rotterdam, Netherlands
 Evolving biology of sarcoma
Jean-Yves Blay, Lyon, France
 Is there a role for neo-adjuvant systemic treatment in STS?
Javier Martin Broto, Palma de Mallorca, Spain
 Innovative combination of targeted agents with radiotherapy
Rick Haas, Amsterdam, Netherlands
 Local treatment after neo-adjuvant therapy
Piotr Rutkowski, Warsaw, Poland
 Conclusions and clinical perspectives
Alessandro Gronchi, Milan, Italy

SCIENTIFIC COMMITTEE

Stefan Sleijfer, Rotterdam, Netherlands, Chair

Thomas Brodowicz, Vienna, Austria
 Robin Jones, Seattle, WA, US
 Bernd Kasper, Mannheim, Germany
 Axel Le Cesne, Villejuif, France
 Cecile Le Pechoux, Villejuif, France
 Javier Martin Broto, Palma de Mallorca, Spain

Aisha Miah, London, UK
 Nicolas Penel, Lille, France
 Piotr Rutkowski, Warsaw, Poland
 Winette van der Graaf, Nijmegen, Netherlands
 Kees Verhoef, Rotterdam, Netherlands

Saturday, 27 September 2014

09:15/ 10:45 **EDUCATIONAL SESSION**
Symptoms in oncology
Chair: Carla Ripamonti, Milan, Italy
Co-Chair: Florian Strasser, St. Gallen, Switzerland
 Organ toxicities from targeted therapies
Carla Ripamonti, Milan, Italy
 Metabolic disorders
Viktor Grünwald, Hannover, Germany
 Complications arising with compliances
Andrea Antonuzzo, Pisa, Italy

11:45/ 12:45 **PATIENT CASES**
Pregnancy and fertility preservation in patients with cancer
Co-Chairs: Hatem A. Azim, Brussels, Belgium and Hamish Wallace, Edinburgh, UK
 How to manage a pregnant woman with cancer
Hatem A. Azim, Brussels, Belgium
 Fertility preservation in the cancer patient
Hamish Wallace, Edinburgh, UK
 Discussion

15:55/ 17:30 **SPECIAL SYMPOSIUM**
Targeting precision medicine toxicity
Chair: Mario Dicato, Luxembourg
Co-Chair: Fausto Roila, Terni, Italy
 Introduction
Mario Dicato, Luxembourg
 Cardiac toxicity
Lillian Siu, Toronto, ON, Canada
 Pulmonary toxicity
Guy Meyer, Paris, France
 Skin toxicity
Caroline Robert, Villejuif, France
 Endocrine toxicity
Fausto Roila, Terni, Italy
 Osteoarticular toxicity
Ignacio Tusquets, Barcelona, Spain
 GI toxicity
Jervoise Andreyev, London, UK

Monday, 29 September 2014

08:00/ 09:00 **CHALLENGE YOUR EXPERT (CYE)**
Thromboembolic disorders in oncology: Present status and novel agents
Speaker: Mario Dicato, Luxembourg

Tuesday, 30 September 2014

08:00/ 09:00 **CYE (REPETITION)**
Thromboembolic disorders in oncology: Present status and novel agents
Speaker: Mario Dicato, Luxembourg

SCIENTIFIC COMMITTEE

Mario Dicato, Luxembourg, Chair

Raphael Catane, Tel Hashomer, Israel
 Petra Feyer, Berlin, Germany
 Pere Gascon, Barcelona, Spain
 Joern Herrstedt, Odense, Denmark
 Ivan Krakowski, Vandoeuvre-les-Nancy, France
 Alex Molassiotis, Hong Kong, China

Carla Ripamonti, Milan, Italy
 César Rodriguez, Salamanca, Spain
 Fausto Roila, Terni, Italy
 Florian Scotté, Paris, France
 Simon Van Belle, Ghent, Belgium

Friday, 26 September 2014

12:00/ 13:15 **ESMO 2014 Opening Session**

ESMO Presidential Address
Rolf A. Stahel, Zurich, Switzerland

Presentation of the ESMO Award by
Josep Tabernero, Barcelona, Spain

ESMO Award lecture
To be announced

Presentation of the ESMO Hamilton Fairley Award by
Josep Tabernero, Barcelona, Spain

ESMO Hamilton Fairley Award lecture
To be announced

Presentation of the ESMO Lifetime Achievement Award by
Josep Tabernero, Barcelona, Spain

ESMO Lifetime Achievement Award lecture
To be announced

ESMO 2014 Scientific Address
Johann S. de Bono, Sutton, UK

Welcome reception

Saturday, 27 September 2014

08:00/ 09:00 **CHALLENGE YOUR EXPERT (CYE)** **Is hormone therapy really harmless in elderly people?** *Speaker: Matti Aapro, Genolier, Switzerland*

11:00/
12:30 **SPECIAL SESSION -ESMO COMMUNITY ONCOLOGY WORKING GROUP (COWG)**
Optimal use of systemic therapy in the palliative setting
Chair: Robert Eckert, Wendlingen, Germany
Co-Chair: Michalis Karamouzis, Athens, Greece

The who and where of cancer care in Europe: Insights from a community oncology survey among ESMO National Representatives
Robert Eckert, Wendlingen, Germany

When to start systemic therapy: Indications for initiation of chemotherapy vs watchful waiting
Ian Tannock, Toronto, ON, Canada

Have a (systemic therapy) break: Optimal duration of systemic therapy in common tumours
Richard Herrmann, Basel, Switzerland

Trials and tribulations: Lifetime experiences of a medical oncologist on chemotherapy intensification
To be announced

It's time to stop: When to initiate palliative / supportive therapy
Sofia Braga, Lisbon, Portugal

Conclusions
Michalis Karamouzis, Athens, Greece

14:15/ 15:45 **JOINT SYMPOSIUM: ESMO EMERGING COUNTRIES COMMITTEE (ECC) - AORTIC-SLACOM-UICC-WHO** **Personalised cancer care in countries with limited resources** *Details to be announced*

16:00/
17:30 **SPECIAL SESSION**
Liquid biopsy: Monitoring tumour-derived cell-free DNA, circulating tumour cells (CTC) and exosomes in patients with solid tumours
Chair: Alberto Bardelli, Turin, Italy
Co-Chair: Carlos Caldas, Cambridge, UK

Introduction
Carlos Caldas, Cambridge, UK

Clinical applications for microRNAs in lung cancer
Carlo Croce, Columbus, OH, US

Circulating tumour cells: Isolation, enrichment and clinical value in breast cancer
Michail Ignatiadis, Brussels, Belgium

Liquid biopsies: Genotyping circulating tumour DNA in colorectal cancer
Alberto Bardelli, Turin, Italy

The potential of circulating tumour cells as a liquid biopsy to guide therapy in prostate cancer
Klaus Pantel, Hamburg, Germany

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Carlos Caldas, Cambridge, UK

Conclusions and clinical perspectives
Alberto Bardelli, Turin, Italy

GENERAL INTEREST

Sunday, 28 September 2014

08:00/ 09:00 **CYE (REPETITION)**
Is hormone therapy really harmless in elderly people?
Speaker: Matti Aapro, Genolier, Switzerland

10:45/ 12:45 **ESMO Clinical Practice Guidelines 1**
Chair: Enriqueta Felip, Barcelona, Spain
Co-Chair: Nicholas Pavlidis, Ioannina, Greece
Introduction to the ESMO CP Guidelines
Enriqueta Felip, Barcelona, Spain
Questionnaire
Nicholas Pavlidis, Ioannina, Greece
Advanced NSCLC case presentation
Speaker: Stefan Zimmermann, Fribourg, Switzerland
Discussant: Solange Peters, Lausanne, Switzerland
Questions and answers
Gastric marginal zone lymphoma or MALT type case presentation
Speaker: To be announced
Discussant: Emanuele Zucca, Bellinzona, Switzerland
Questions and answers
High-grade glioma case presentation
Speaker: Katharina Seystahl, Zurich, Switzerland
Discussant: Roger Stupp, Zurich, Switzerland
Questions and answers
Head & neck cancer: HPV case presentation
Speaker: To be announced
Discussant: Lisa Licitra, Milan, Italy
Questions and answers

13:45/ 15:45 **ESMO Clinical Practice Guidelines 2**
Chair: Andrés Cervantes, Valencia, Spain
Co-Chair: George Pentheroudakis, Ioannina, Greece
Introduction to the ESMO CP Guidelines
Andrés Cervantes, Valencia, Spain
Questionnaire
George Pentheroudakis, Ioannina, Greece
Advanced melanoma case presentation
Speaker: Simone Goldinger, Zurich, Switzerland
Discussant: Reinhard Dummer, Zurich, Switzerland
Questions and answers
Gestational trophoblastic disease case presentation
Speaker: Fieke Froeling, London, UK
Discussant: Michael Seckl, London, UK
Questions and answers
Waldenström's macroglobulinaemia case presentation
Speaker: To be announced
Discussant: Christian Buske, Ulm, Germany
Questions and answers
Cervical cancer case presentation
Speaker: To be announced
Discussant: Cristiana Sessa, Bellinzona, Switzerland
Questions and answers

16:00/ 17:30 **SPECIAL SESSION - ESMO EMERGING COUNTRIES AND PUBLIC POLICY COMMITTEES**
Availability of anti-neoplastic medicines in Europe
Details to be announced

16:00/ 17:30 **JOINT SYMPOSIUM: ESMO - EONS**
Oral tumour therapy: Collaboration and coordination of healthcare professional activities to enhance patient adherence
Co-Chairs: Andrés Cervantes, Valencia, Spain and Anita Margulies, Zurich, Switzerland
Issues and challenges in oral tumour therapy adherence
Anita Margulies, Zurich, Switzerland
Clinical issues in patients receiving oral tumour therapy: How can we improve adherence?
Alfredo Carrato, Madrid, Spain
Nurse led clinics: Involvement in patient management and follow up
To be announced
Oral tumour therapy in Emerging Countries: Special problems encountered
Alexandru Eniu, Cluj Napoca, Romania
Options and strategies: Project in action: Oral tumour therapy-adherence and safety
Anita Margulies, Zurich, Switzerland
Conclusions
Andrés Cervantes, Valencia, Spain

Monday, 29 September 2014

08:00/ 09:00	CHALLENGE YOUR EXPERT (CYE) Current diagnosis and treatment of CUP <i>Speaker: George Pentheroudakis, Ioannina, Greece</i>
09:15/ 10:45	SPECIAL SESSION Precision medicine: Panacea or false dawn? <i>Chair: Johann S. de Bono, Sutton, UK</i> <i>Co-Chair: José Baselga, New York, NY, US</i> Introduction <i>Johann S. de Bono, Sutton, UK</i> Visualising the true spectrum of cancer: Will we get convergence from divergence? <i>Peter Campbell, Cambridge, UK</i> Drug registration strategies: How will these change with precision medicine? <i>José Baselga, New York, NY, US</i> Inpatient heterogeneity and clonal evolution: What precision medicine? <i>Charles Swanton, London, UK</i> Precision medicine: Panacea or false dawn? <i>Andrew Hughes, Macclesfield, UK</i> Conclusions <i>Johann S. de Bono, Sutton, UK</i>
11:00/ 12:30	JOINT SYMPOSIUM: ESMO - ASCO The evolution of the clinical trials landscape <i>Co-Chairs: Rolf A. Stahel, Zurich, Switzerland and Peter Yu, Sunnyvale, CA, US</i> Introduction <i>Peter Yu, Sunnyvale, CA, US</i> Novel molecular studies to inform the conduct of oncology clinical trials: from battle to master protocols <i>Roy Herbst, New Haven, CT, US</i> Adapting organisation and research infrastructures at Gustave Roussy for today's clinical research programmes <i>Alexander M.M. Eggermont, Villejuif, France</i> Can Collaborative Molecular Screening Platforms (CMSPs) support new forms of cancer clinical research? The example of the EORTC SPECTA programme <i>Denis Lacombe, Brussels, Belgium</i> The evolution of clinical trials: Randomised controlled trials to real world studies <i>Gary Lyman, Seattle, WA, US</i> Conclusions <i>Rolf A. Stahel, Zurich, Switzerland</i>

14:15/ 15:45	JOINT SYMPOSIUM: ESMO - SEOM Investigation driven precision oncology <i>Co-Chairs: Rolf A. Stahel, Zurich, Switzerland and Pilar Garrido, Madrid, Spain</i> Introduction <i>Pilar Garrido, Madrid, Spain</i> Translating breast cancer genomics into clinic <i>Miguel Martin, Madrid, Spain</i> Can we do better with our current therapies for NSCLC? The Spanish Lung Cancer Group approach <i>Rafael Rosell, Badalona, Spain</i> TTD contribution to precision oncology <i>Enrique Aranda, Cordoba, Spain</i> The European perspective of academic research: The way to move forwards <i>To be announced</i> Conclusions <i>to be announced</i>
16:00/ 17:30	EDUCATIONAL SESSION Cancer in young adults (18-35) <i>Chair: Sophie Fosså, Oslo, Norway</i> <i>Co-Chair: George Pentheroudakis, Ioannina, Greece</i> Epidemiology, risk factors, genetics and molecular biology <i>Sophie Fosså, Oslo, Norway</i> Managing the most common tumours affecting young adults: Peculiarities, controversies and clinical research <i>Valerie Laurence, Paris, France</i> Follow up and long term toxicity of young adult cancer survivors <i>Daniel Stark, Leeds, UK</i>
16:00/ 17:30	SPECIAL SESSION - RARE CANCERS EUROPE How clinical trials could have been done, and were not, in rare cancers <i>Details to be announced</i>

Tuesday, 30 September 2014

08:00/ 09:00	CYE (REPETITION) Current diagnosis and treatment of CUP <i>Speaker: George Pentheroudakis, Ioannina, Greece</i>
09:00/ 13:00	CONGRESS HIGHLIGHTS The best of the ESMO 2014 Congress

Controversy sessions will be included in the programme and details will be made available at the same time as the abstract-related sessions

Friday, 26 September 2014

- 14:00/ 17:00 **YO MASTERCLASS**
ESMO YOs meet the EACR: Integrating basic science into clinical research
Chair: Raffaele Califano, Manchester, UK
Co-Chair: Leticia De Mattos-Arruda, Barcelona, Spain
 Functional characterisation of tumours using patient-derived models - therapeutic implications
Speaker: Joan Seoane, Barcelona, Spain
Session Shooter: Matthias Preusser, Vienna, Austria
 Inter and intra-tumour genetic heterogeneity: Challenges for targeted therapy
Speaker: Carlos Caldas, Cambridge, UK
Session Shooter: Erika Martinelli, Naples, Italy
 Circulating biomarkers: What does this mean today?
Speaker: Klaus Pantel, Hamburg, Germany
Session Shooter: Sophie Postel-Vinay, London, UK
 Next generation of clinical trial design
Speaker: Timothy Yap, Sutton, UK
Session Shooter: Jesus Corral, Seville, Spain

- 17:15/ 17:45 **VESALIUS TALK**
Paving your own path to success
Mentors: Christoph Zielinski, Vienna, Austria;
Angelo Di Leo, Prato, Italy and Nicholas Pavlidis, Ioannina, Greece

Saturday, 27 September 2014

- 08:00/ 08:45 **YO BREAKFAST**
How to address the media: Practical advice for young oncologists
Session Coordinators: Margaret Hutka, London, UK and Matthias Preusser, Vienna, Austria
Speaker: Jilly Carter, Wallingford, UK

Sunday, 28 September 2014

- 08:00/ 08:45 **YO BREAKFAST**
How to find the right work-life balance: Time management for young oncologists
Session Coordinators: Giannis Mountzios, Athens, Greece and Susana Banerjee, London, UK
Speaker: Pia Osterlund, Helsinki, Finland

Monday, 29 September 2014

- 08:00/ 08:45 **YO BREAKFAST**
Risks and boundaries: The doctor / cancer patient relationship
Session Coordinators: Mila Petrova, Sofia, Bulgaria and Valentina Guarnieri, Padua, Italy
Speaker: Lesley Fallowfield, Brighton, UK
- 09:00/ 10:30 **YO FORUM**
Tips and tricks for cancer researchers in training
Chair: Valentina Guarnieri, Padua, Italy
Co-Chair: Karin Jordan, Halle, Germany
 The ideal mentor and the impact on your career
Speaker: Peter Schmid, London, UK
Session Shooter: Mila Petrova, Sofia, Bulgaria
 Practical advice on how to write a clinical trial protocol
Speaker: To be announced
Session Shooter: Nikita Volkov, St. Petersburg, Russian Federation
 The importance of a well written grant application
Speaker: Fatima Cardoso, Lisbon, Portugal
Session Shooter: Sophie Postel-Vinay, London, UK
 Research project completed - now write your paper!
Speaker: Kari Skinningsrud, Lillestrøm, Norway
Session Shooter: Camilla Qvortrup, Odense, Denmark

- 11:00/ 12:30 **YO SPECIAL SESSION**
Fellowships in Europe: Educational opportunities for young oncologists
Chair: Giampaolo Tortora, Verona, Italy
Co-Chair: Raffaele Califano, Manchester, UK
 Introduction
Giampaolo Tortora, Verona, Italy
 The ESMO Fellowship Programme
Susana Banerjee, London, UK
 Practical tips from a former fellow
Leticia De Mattos-Arruda, Barcelona, Spain
 Best fellowship project 1
Floriana Morgillo, Naples, Italy
 Best fellowship project 2
Hatem A. Azim, Brussels, Belgium
 Conclusions
Raffaele Califano, Manchester, UK and Giampaolo Tortora, Verona, Italy
 Awards: Presentation of the ESMO 2014 fellows and the 2013 best exam

YOUNG ONCOLOGISTS COMMITTEE

Raffaele Califano, Manchester, UK, Chair

Susana Banerjee, London, UK
 Jesus Corral, Seville, Spain
 Evandro De Azambuja, Brussels, Belgium
 Leticia De Mattos-Arruda, Barcelona, Spain
 Valentina Guarnieri, Padova, Italy
 Margaret Hutka, London, UK
 Karin Jordan, Halle, Germany

Erika Martinelli, Naples, Italy
 Giannis Mountzios, Athens, Greece
 Mila Petrova, Sofia, Bulgaria
 Sophie Postel-Vinay, London, UK
 Matthias Preusser, Vienna, Austria
 Camilla Qvortrup, Odense, Denmark
 Nikita Volkov, St. Petersburg, Russian Federation

**STOP SEARCHING
START FINDING**

**FIND WHAT YOU'RE
LOOKING FOR ON
ONCOLOGYPRO**

anderson-group.com

THE ONLINE ACCESS TO ESMO'S SCIENTIFIC AND EDUCATIONAL CONTENT.

Your one-stop shop for exclusive medical oncology content, from news and conference presentations to guidelines, handbooks and treatment factsheets. All available at your desk, or on the go.

MEDICAL ONCOLOGY IS A FAST-EVOLVING FIELD,
ONCOLOGYPRO WILL HELP YOU KEEP UP-TO-DATE.

oncologypro.esmo.org

Major sponsors



Main sponsors



PATIENT ADVOCACY TRACK

Saturday, 27 September 2014

10:00/13:00 **Cancer research**

Clinical trials: Making statistics a little bit easier to understand!
Clinical trials – Endpoints
Patient involvement in cancer clinical research
Introduction: Generating patient data, tissue and experiences...

14:00/15:30 **Treatment & living (part 1)**

ESMO Patient Cancer Guides
Cancer & nutrition

16:00/17:45 **Treatment & living (part 2)**

Patient interaction with multidisciplinary teams (MDTs)
Highlighting some social challenges

17:45 **End of the 1st day – Get together / Networking**

Sunday, 28 September 2014

10:00/13:00 **Capacity building**

The ESMO "Patient Advocacy Best Practice Award" 2014
Why strategic planning is important and valuable for patient groups?

14:00/15:30 **Patient advocacy (Part 1)**

An interesting journey through European healthcare politics
RARE CANCERS in EUROPE: More common than you think!

16:00/17:30 **Patient advocacy (Part 2)**

European cross border healthcare directive

17:30 **End of the 2nd day – Farewell**

ESMO PATIENT ADVOCACY TRACK TASK FORCE

Lorenz Jost, Kantonsspital and Chair of the ESMO CPWG Switzerland

Raphael Catane
Sheba Medical Centre, Israel
Philip Davies
European Cervical Cancer Association, UK
Francesco De Lorenzo
European Cancer Patient Coalition, Italy
Louis Denis
Europa Uomo, Belgium
Jan Geissler
CML Advocates Network, Germany
Gabriela Kornek
Medical University of Vienna, Austria
Stella Kyriakides
Europa Donna Cyprus, Cyprus

Anita Margulies
European Oncology Nursing Society, Switzerland
Kathy Oilver
International Brain Tumours Alliance, UK
Zorana Stokic
Europacoln, Serbia
Wendy Tse Yared
Association of European Cancer Leagues, Belgium
Stefania Vallone
Global Lung Cancer Coalition, Italy
Anita Waldmann
Myeloma Euronet, Germany
Markus Wartenberg
Sarcoma Patients EuroNet, IKCC, Germany

Final details of the programme will be published online at esmocongress.org



MADRID 2014 ESMO congress

ander-groep.com

